Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, brought in $25 million to push its lead candidates through mid- and late-stage trials and prepare for commercialization.
Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo--but only after the company removed data from four "extreme" responders from its analysis.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Acne remedies and ADHD drugs are big markets for the teen demographic--but how exactly are young consumers interpreting advertisements for these products? A soon-to-launch FDA study aims to find out exactly that.
To hear Shire tell it, there aren't many adequate and well-controlled drug studies in preschool-aged children with ADHD. But never fear, the company says: It's agreed to a written request by the FDA to investigate its ADHD drug Vyvanse in children aged 4 to 5, with a potential 6-month exclusivity boost for the drug on the line.
Psychiatric meds have been growth superstars for more than a decade, generating billions for their makers. But generics have flooded the playing field, and save a few select on-patent meds, today's top-selling psych meds, dollarwise, are lowercase copycats, not capital-letter brands.
Attention deficit hyperactivity disorder drugs like Ritalin have been on the FDA shortage list for a variety of reasons. Now add to that packaging problems which have led Novartis to recall nearly 22,000 bottles.
There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.
Cambridge, MA's Neurovance has reeled in a $6.3 million extension to its earlier Series A, money it'll use to push forward with a promising nonstimulant treatment for attention deficit hyperactivity disorder.
Texas oral drug delivery specialist Neos Therapeutics pulled in $15.5 million in a Series C round of financing to help propel its line of ADHD controlled-release treatments to the market.